Engraftment
| Median number of CD34+ cells reinfused, n (range) | 6 (2.4-15.5) |
| Median time to ANC > 0.5 × 109/L, d (range) | 10 (8-12) |
| Median time to PLT > 20 × 109/L, d (range) | 13 (8-39) |
| Median time to PLT > 50 × 109/L, d (range) | 16 (11-51) |
| Documented infections, n (%) | 3/43 (7%) |
| Fever of unknown origin, n (%) | 22/43 (51%) |
| Median days on parenteral antibiotics, n (range) | 9 (3-22) |
| Median days on G-CSF, n (range) | 8 (8-13) |
| Median days with fever, n (range) | 2 (1-7) |
| Median days to hospital discharge, n (range) | 24 (20-57) |
| Second hospitalization, n | 3/43 |
| Late infections, n | |
| HSV-6 | 1/43 |
| CMV | 1/43 |
| Median number of CD34+ cells reinfused, n (range) | 6 (2.4-15.5) |
| Median time to ANC > 0.5 × 109/L, d (range) | 10 (8-12) |
| Median time to PLT > 20 × 109/L, d (range) | 13 (8-39) |
| Median time to PLT > 50 × 109/L, d (range) | 16 (11-51) |
| Documented infections, n (%) | 3/43 (7%) |
| Fever of unknown origin, n (%) | 22/43 (51%) |
| Median days on parenteral antibiotics, n (range) | 9 (3-22) |
| Median days on G-CSF, n (range) | 8 (8-13) |
| Median days with fever, n (range) | 2 (1-7) |
| Median days to hospital discharge, n (range) | 24 (20-57) |
| Second hospitalization, n | 3/43 |
| Late infections, n | |
| HSV-6 | 1/43 |
| CMV | 1/43 |
ANC indicates absolute neutrophil count; and PLT, platelet count.